Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration

被引：2

作者：

Teo, Kelvin Yi Chong ^{[1
]}

Eldem, Bora ^{[2
]}

Joussen, Antonia ^{[3
]}

Koh, Adrian ^{[4
]}

Korobelnik, Jean-Francois ^{[5
,6
]}

Li, Xiaoxin ^{[7
]}

Loewenstein, Anat ^{[8
]}

Loevestam-Adrian, Monica ^{[9
]}

Navarro, Rafael ^{[10
]}

Okada, Annabelle A. ^{[11
]}

Pearce, Ian ^{[12
]}

Rodriguez, Francisco ^{[13
]}

Wong, David ^{[14
]}

Wu, Lihteh ^{[15
]}

Zur, Dinah ^{[8
]}

Zarranz-Ventura, Javier ^{[16
]}

Mitchell, Paul ^{[17
]}

Chaudhary, Varun ^{[18
,19
]}

Lanzetta, Paolo ^{[20
]}

机构：

[1] Singapore Natl Eye Ctr, Singapore, Singapore

[2] Hacettepe Univ, Sch Med, Dept Ophthalmol, Ankara, Turkiye

[3] Charite Univ Med Berlin, Berlin, Germany

[4] Camden Med Ctr, Singapore, Singapore

[5] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France

[6] Univ Bordeaux, INSERM, BPH, UMR1219, F-33000 Bordeaux, France

[7] Xiamen Univ, Xiamen Eye Ctr, Xiamen, Peoples R China

[8] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel

[9] Lund Univ Hosp, Dept Ophthalmol, Lund, Sweden

[10] Inst Microcirugia Ocular, Retina & Vitreous Dept, Barcelona, Spain

[11] Kyorin Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan

[12] Royal Liverpool Univ Hosp, Liverpool, England

[13] Univ del Rosario, Escuela Med & Ciencias Salud, Fdn Oftalmol Nacl, Bogota, Colombia

[14] Univ Toronto, St Michaels Hosp, Unity Hlth Toronto, Div Cardiol, Toronto, ON, Canada

[15] Macula Vitreous & Retina Associates Costa Rica, San Jose, Costa Rica

[16] Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain

[17] Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Dept Ophthalmol, Sydney, Australia

[18] St Josephs Healthcare Hamilton, Hamilton Reg Eye Inst, Hamilton, ON, Canada

[19] McMaster Univ, Dept Surg, Hamilton, ON, Canada

[20] Univ Udine, Dept Med Ophthalmol, Udine, Italy

来源：

EYE | 2025年 / 39卷 / 05期

关键词：

ENDOTHELIAL GROWTH-FACTOR; RETINAL FLUID VOLUMES; INTRAVITREAL AFLIBERCEPT; VISUAL-ACUITY; RANDOMIZED-TRIAL; FACTOR THERAPY; RANIBIZUMAB; EXTEND; SAFETY; EFFICACY;

D O I：

10.1038/s41433-024-03370-0

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Practice patterns for neovascular age-related macular degeneration (nAMD) have evolved from the landmark registration trials of vascular endothelial growth factor (VEGF) inhibitors. Non-monthly regimens like treat-and-extend (T&E) have become popular due to their effectiveness in clinical practice. T&E regimens attempt to limit the burden of visits and treatments by allowing progressively longer treatment intervals, but in so doing, are potentially associated with the expense of treating quiescent disease. This is acceptable to many patients and their ophthalmologists but can still be problematic in the real-world. Recent studies have further refined the T&E approach by allowing for quicker and longer extension of treatment intervals when less severe disease is detected. With newer drugs offering increased durability, a shift to longer regular intervals may emerge as a new practice pattern for VEGF inhibitor therapy. This review aims to consolidate the current literature on the most effective treatment patterns and update treatment guidelines based on options that are now available. It also summarises new aspects of nAMD management that may help to further refine current practice.

引用

页码：860 / 869

页数：10

共 88 条

[1] Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration [J].